The conventional classification of acute myocardial infarction (AMI) into ST-segment elevation (STEMI) and non-ST-segment elevation (NSTEMI) has long guided clinical decision-making. However, emerging ...

SAN FRANCISCO, California — A small, phase 2 study, with a biomarker test for its primary end point, offers some encouraging hints that the P-selectin antagonist inclacumab may be able to reduce ...

Among patients presenting to the hospital with NSTEMI, an early invasive strategy based on symptom-to-catheter time is associated with a lower risk of all-cause mortality at 3 years, according to new ...

LONDON, England—An invasive strategy of coronary angiography, and revascularization if appropriate, is no better than conservative medical therapy for reducing the risk of cardiovascular mortality or ...

The diagnostics advisory committee considered evidence on high-sensitivity troponin tests for the early rule out of non-ST-segment elevation myocardial infarction (NSTEMI) from several sources. Full ...

Medical Management/Treatment Initial treatment for suspected STEMI and NSTEMI requires a loading dose of nonenteric coated ASA at 162 to 325 mg (unless contraindicated), nitroglycerin in response to ...

A new study published in the journal of JACC Advances revealed that recreational drug use detected at the time of admission ...

Acute coronary syndrome (ACS) encompasses a spectrum of clinical conditions precipitated by sudden, reduced blood flow to the myocardium. Often resulting from coronary plaque rupture and subsequent ...